A Controlled Study of Uric Acid on the Progression of IgA Nephropathy

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Allopurinol; Uric Acid

Criteria

Inclusion Criteria:

1. Subjects of either sex, more than 18 years old, the range of age is 18 to 70 year old.

2. Biopsy-proven IgA nephropathy.

3. Proteinuria between 0.15g/d and 3.0g/d; and serum albumin level>3.5g/dl.

4. Serum creatinine < 3 mg/dl.

5. Uric acid > 6 mg//dl (360umol/dl) in female; Uric acid >7mg/dl (420umol/dl ) in male.

6. No history of taking ACEI or ARB within 2 weeks.

7. Blood pressure < 180/110 mmHg.

8. Subjects who agree to participate in the study and sign the informed consent.

Exclusion Criteria:

1. Patients who have received prednisone or immunosuppressive drugs within 2 months.

2. Patients who must take ACEI or ARB due to other diseases.

3. Patients who have the history of allergy to allopurinol.

4. Unwillingness to follow the study protocol.

5. Active gout within 4 weeks.

6. Pregnancy or unwillingness to use contraception.